Jade Biosciences Acquired | Healthcare M&A Deal

Jade Biosciences has completed the acquisition of Jade Biosciences, a pharmaceuticals business in San Francisco, for $172.5 million. Jade Biosciences is a clinical-stage biotechnology company developing best-in-class therapies for autoimmune diseases, supporting programs through clinical trials and preclinical studies. The company plans to use the healthcare M&A proceeds to fund manufacturing, research and development, capital expenditures, and working capital in California. The other acquisition closed a public offering of 11,500,000 shares of common stock at $15.00 per share, including full exercise of underwriters’ option to purchase 1,500,000 additional shares, with gross proceeds of $172.5 million.